Patients tolerant to a kidney graft display a specific blood cell transcriptional pattern but results from five different studies were inconsistent, raising the question of relevance for future clinical application. To resolve this, we sought to identify a common gene signature, specific functional and cellular components, and discriminating biomarkers for tolerance following kidney transplantation. A meta-analysis of studies identified a robust gene signature involving proliferation of B and CD4 T cells, and inhibition of CD14 monocyte related functions among 96 tolerant samples. This signature was further supported through a cross-validation approach, yielding 92.5% accuracy independent of the study of origin. Experimental validation, performed on new tolerant samples and using a selection of the top-20 biomarkers, returned 91.7% of good classification. Beyond the confirmation of B-cell involvement, our data also indicated participation of other cell subsets in tolerance. Thus, the use of the top 20 biomarkers, mostly centered on B cells, may provide a common and standardized tool towards personalized medicine for the monitoring of tolerant or low-risk patients among kidney allotransplant recipients. These data point to a global preservation of genes favoring the maintenance of a homeostatic and 'healthy' environment in tolerant patients and may contribute to a better understanding of tolerance maintenance mechanisms.
Patients tolerant to a kidney graft display a specific blood cell transcriptional pattern but results from five different studies were inconsistent, raising the question of relevance for future clinical application. To resolve this, we sought to identify a common gene signature, specific functional and cellular components, and discriminating biomarkers for tolerance following kidney transplantation. A meta-analysis of studies identified a robust gene signature involving proliferation of B and CD4 T cells, and inhibition of CD14 monocyte related functions among 96 tolerant samples. This signature was further supported through a cross-validation approach, yielding 92.5% accuracy independent of the study of origin. Experimental validation, performed on new tolerant samples and using a selection of the top-20 biomarkers, returned 91.7% of good classification. Beyond the confirmation of B-cell involvement, our data also indicated participation of other cell subsets in tolerance. Thus, the use of the top 20 biomarkers, mostly centered on B cells, may provide a common and standardized tool towards personalized medicine for the monitoring of tolerant or low-risk patients among kidney allotransplant recipients. These data point to a global preservation of genes favoring the maintenance of a homeostatic and 'healthy' environment in tolerant patients and may contribute to a better understanding of tolerance maintenance mechanisms. Transplantation is the treatment of choice for end-stage renal disease. Recent advances in immunosuppression (IS) have improved management of acute rejection and graft survival. 1 However, due to their toxicity, these drugs have numerous deleterious side effects and only a marginal effect on long-term rejection. [2] [3] [4] [5] Tolerance is thus increasingly regarded as an ideal solution. 6 This situation, mainly corresponding to incompliant cases, has been observed in renal transplantation 7, 8 and current estimates report roughly 100 cases. 9 Besides, efforts have been devoted by the European and US transplant community to decipher the regulatory mechanisms and to identify noninvasive biomarkers. These studies could report several gene lists, with evidence converging towards the potential implication of B cells as attested by the identification of numerous related markers, [10] [11] [12] [13] [14] a unique differentiation profile, 15 and an increasing number of several subtypes in the blood of these patients. 13, 14, 16, 17 Although informative, these lists poorly overlapped, raising question about the pertinence of the results for future clinical application. However, as recently exemplified by the identification of rejection markers across multiple transplanted organs, 18 comparing and integrating data from several studies by meta-analysis 19 is an ideal solution to increase reliability and consistency in the results and conclusions. Hence, when applied to the five existing tolerance-related studies, [10] [11] [12] [13] [14] such meta-analysis may also enable to reconcile data.
In this context, the first objective of our work was to define a robust gene signature 20 indicative of tolerance. The second objective was to define specific functional and cellular components supported by the signature, as previously defined, 20 and that may bring clues for the understanding of peripheral regulatory mechanisms. The third objective was to validate a subset of markers that could be further used in clinics for the stratification of kidney recipients with a low risk of rejection. -cell  molecules (AFF3, BLK, BLNK, CD22, CD79B, FCER2, FCRL2,  ID3, IGKC, IGLL1 , MS4A1, MZB1 and TCL1A) belonging to the top-ranked gene lists (Supplementary Figure SI5 online) from the different studies. [10] [11] [12] [13] [14] Altogether, these data show that integrative meta-analysis can identify a robust gene meta-signature of tolerance.
Gene set analysis corroborated functionality and revealed the possible involvement of specific cell populations in tolerance A screening of the compendium of gene sets retained the 100 best hits for each cluster (K1, K2, and K10; Figure 3 , Supplementary Figure SI10 online). Although significant (Po0.00001), these overlaps were partial (mean coverage ¼ 8.89±4.82%) but displayed good functional congruence (Figure 3a) : the 100 best hits converged to cell proliferation and cell adhesion for K1, inflammatory response for K2 and lymphocyte activation for K10. A similar analysis with a collection of blood transcriptional modules (Supplementary Figure SI11 online) 21 significantly (Po0.001) linked K2 genes to proinflammatory-related monocyte modules, whereas K10 genes were linked to B-cell and T-cell modules. Particular results (Figure 3b ) from different studies [22] [23] [24] [25] [26] [27] illustrate the link to T CD4 (panel 1) 26 and especially B (panels 2-4 and 6) [23] [24] [25] 27 lymphocytes at various differentiation stages. For instance (panels 1 and 4), 24, 26 K1 was remarkably enriched (Po1.00E À 16) in early proliferating T-and B-cell markers. Conversely, markers of differentiated cell subsets were significantly linked to K10: P ¼ 1.01E À 13 for T CD4 þ 26 and P ¼ 7.55E À 09 for B cells. 24 Virtual microdissection analysis revealed the clear participation of B cells, CD4 T lymphocytes, and monocytes in tolerance
The TOL signature (K1, K2, and K10; Figure 4a ) was compared with clusters from various tissue ( Figure 4b ) and blood cell (Figure 4c ) samples. This comparison identified K1 as a proliferation cluster (for example, AURKB, CCNB2, CDC20, CHEK1, NEK2, and PLK4) gathering 67% (P ¼ 6.31 E À 13) and 73% (P ¼ 1.04E À 13), respectively, of the genes from proliferating tissues (for example, testis and skin; Figure 4b ) or cells (early blood precursors; Figure 4c ). K2 and K10 gathered 90% (P ¼ 2.30E À 20) of immune tissue markers (for example, bone marrow, thymus, spleen, and lymph nodes; Figure 4b) showing their immunological specificity. K2 contained 82% (P ¼ 3.44E À 85) of the granulocyte/ monocyte lineage markers ( Figure 4c ) and corresponded to a CD14 monocyte cluster (for example, CD14, CD163, CD68, ITGAM, ITGB2, and PECAM1; Figure 4d ). K10 contained 86% (P ¼ 5.12E À 40) of the T lineage makers (Figure 4c ) that were preferentially expressed in naive and differentiated CD4 subsets (for example, CD247, CD28, CD48, CD5, LAT, and MAL; Figure 4d ). It also harbored 71% (P ¼ 9.31E À 10) of the B lineage markers (Figure 4c ) expressed in naive and differentiated subsets (for example, BLNK, CD22, CD40, CD79B, FCER2, and MS4A1; Figure 4d ). Altogether, these data suggest the involvement of different cell subsets in tolerance, as attested by the specific expansion and differentiation of B and CD4 T cells, and the inhibition of monocyte functions. TF  TF  TF  TF  TF  TF Generalization of the results using external data confirmed the biological relevance (functionality and cellularity) of the tolerance gene signature and its reproducibility
To assess the reproducibility of the signature with external data, similar trends of expression were searched in a collection of data sets using co-expression ( ) harbored the same pattern in terms of rank differences. A textmining analysis revealed that 70% (P ¼ 3.40E À 14) of the matched studies were related to blood (Supplementary Figure  SI12 online) or other cell subsets (mononuclear cells: P ¼ 3.45E À 10; lymphocytes: P ¼ 2.88E À 07; B cells:
Altogether, these data show that genes from the signature are recurrently associated with the same functionally related neighbors of co-expression and display a TOL-like pattern in numerous blood cell-related studies. . The discriminative propensity of each meta-cluster to discriminate tolerant (TOL) from the control group of stable recipients (MIS and STA) was assessed by a Student's t-test (T in blue) applied on its median profile and a Fisher's exact test (F in blue) applied on the contingency of its dendrogram (see legend, 'statistics'): resulting P-values are indicated on the right of each meta-cluster using shades of blue (see color legend). The three most differential ones (TOL vs. STA/MIS, Po0.00001) with the two tests (namely K1, K2, and K10) are denoted by arrows. (d) Definition of the meta-signature of tolerance. For each of the three most differential (Po0.00001) meta-clusters (K1, K2, and K10) pertaining to the signature, a heat map visualization is depicted. Information provided includes the following: the median profile (M) of the cluster and the P-value from the Student's t-test (T) applied to it; the contingencies (number of TOL, MIS, and STA samples) from the two main branches of the dendrogram (blue and black, respectively); and the P-value from the Fisher's exact test applied to them. For each meta-cluster, the top ten significant Gene Ontology (GO) terms from functional annotation analysis are also given and summarized by a representative term (right side of the panel). Terms with an asterisk indicate significance of the enrichment but sensitivity to multiple testing corrections (FDR-adjusted P-values). CSR, class-switch recombination. 0   ISG15  CD24  RFC4  HINT1  NME1  AKR1C3  UBR4  CCL26  GPNMB  SEPP1  TGFBI  RUNX1  AKR1C1  SPP1  BCAT1  PHLDA2  EDN1  PLAT  KANK1  IRF4  SLC7A11  CTSL2  CD38  USP18  INHBA  IFI27  WNT5A  LPCAT3  PMP22  PTGR1   EVI2A  CSK  LIMK1  ACER3  LSP1  CTSD  LTA4H  TNFSF13  TLR4  CD4  PECAM1  F13A1  GPX3  ALDHLA1  CD302  HMOX1  MAX  FGL2  PLCL2  FYB  CEBPD  MARCO  MAFB  CD14  HNMT  CD163  ZAK  TLR8  MYD88  C3AR1  SPTLC2  RAC2  SPINT1  DUSP6  NP  TNFSF10  PIK3AP1  LILRB2  OAS1  GBP1  IFI44L  GCH1  MGST1  EMR1  MX2  CSF2RA  TSC22D1   IL27RA  HLA-DMB  FCER2  GARM  CD37  LGMN  HLA-DRB4  LAIR1  AOP3  RHOH   CD40  IL7R  TRAF1  TCF4  NRP1  MARCKSL1  TCF3   LGALS1  SPON1  DNTT  CDC20  RRM2  TOP2A  MGC29506  IGLL1  CD24  IRF4  ID3   ALDH1A1  TNFSF10  LYZ  HCK  HGF  CEBPD  CSF 1R  VCAH  F13A1  IRF2  CTBP2  LILRB2  RHOB   PTK2  HSPA5  ANK3  CCR7  LGMH  IRF8  IL 7R  HS 3ST  LTB  BLNK  MLL  CD22  CYFIP2  BLK  TCF3  CD 79B  LEF1  TCF4  PCDH9  CIITTA  MS4A1  FHIT  TCL1A  HLA-DOA1  HLA-DRB4   HSPA5   LAT   PLK4  TCEB1  HSPA4  PLK4  CDKN3  TMEM97  MKI67  CENPE  CDC2  TOP2A  NEK2  FOXM1  CDC20  KIAA0101  ALDH7A1  TYMS  RFC4  HMMR  RRM2  CKS2  MTHFD2  IRF4  YARS  PSME2  GLDC  PSMA3  TUBG1  NME1  KANK1  COX7B  LGALS1  RNASE1  PPARG  RUNX1  COL11A1  CD38  GPNMB  CFB  PAX6  SNRPC  SDC1  CXADR  RUNX1T1  MITF  PFN2  COX6C  CXCL12   MAX  PRKCB  GCH1  FGR  KYNU  TKT  APP  MAPK1  PRKDC  IOGAP1  PGK1  OSTF1  WARS   LILRB4  LSP1  NP  CASP1  ANG  HDLBP  SELPLG  FGL2  CCR2   GPX3  DAPK1  TNFAIP2  CST3  ALDH1A1  FBP1  LYZ  CD74  MX2  CUX1  GRN  IFI44L   HLA-DMB  CD83  CD37  SATB1  CD52  CCND3  RPS21  LTB  CIITA  IRF8  NFKB1  CCR7  BLK  RHOH  TRAF1  MARCKSL1  CD22  HLA-DQA1  MS4A1  TUBB  CCT2  LDHB  BAK1  AOP3  HSPA5  CD180  PRPS2  IGKC  HOXB2  LGMN  IL7R  AIP2  TCL1A  CD40   CYBA   IFI30   MGC29506  CD38  DNTT  MYB  AURKB  FANCG  STMN1  MKI67  NCAPG  BIRC5  AURKA  CDC2  FOXM1  KIAA0101  HMGB3  BUB1  CCNB2  NUF2  TOP2A  PBK  MELK  TUBA1B  CDKN3  ASPM  CENPF  NEK2  TK1  CENPE  HMMR  RRM2  PTTG1  HSPA4  TYMS  NME1  ID3  CLIC4  LAP3  SCD   CKS2   YARS   GBP1  S100A4  CTSB   TNFSF10  CASP1  ANXA1  TNFRSF 1B  ATP11A  CTSS  STAT1  IFI44L  PLCL2  GCH1  HLA-E  SELPLG  CD53  RAC2  EVI2A  HCLS1  FYB  ITGB2  PRKCB  SYK  CUX1  DAPK1  WARS  TSC22D1  TKT  YWHAE  DUSP6  ZAK  PLSCR1  LHFPL2  VIM  GAPDH  TNFSF4   ATP1A1  DPP4  RSL1D1  ANK3  SESN1  IGKC  PTK2  SKI  KDSR  SMAD3  TNFRSF25  S1PR1  CCR7  SERPINB9  CD5  C5orf39  CYTH1  IL10RA  FHIT  IL27RA  CD28  ITK  CD6  IL7R  CD48  IL16  SLAMF1  LTB  SATB1  IKZF1   CYFIP2  LAT  CD52  DGKA  RHOH  IL23A  LEF1  MAL  TCF7  LCK  AOP3  CCND3  FUBP1  MYC  IRF8  HLA-DRB4  HLA-DRA  TCL1A  TBCD  MARCKSL1  C10BP  PRPS2  ATP5B  GMPS  WHSC1  PCDH9  TUBB  HSPA5  TCF4  AKAP2  MIF   CD247   SAMHD1   ALDH7A1   CD24   CHEK--MTHFI  CDC2:  COPS:   CTSB  HDLB1  PGK1  LMO2  PIL:31  CD 74   OXCT--MS4A--CD 8:3  IL 7R  TCF4   RBP4  TRAF3  SCD  ID3  IL4  AKR1C1  DNTT  IGLL1  CTSL2  MTHFD2  STMN1  HMGB3  TK1  RRM2  CHEK1  LGALS1  AURKB  SLC29A1  CCIB2  CDC2  TUBA1B  CKS2  TOP2A  BUB1  KIAA0101  HMMR  CENPE  NEK2  MELK  CDC20  MKI67  AURKA  PLK4  CDKN3  PTGR1  MYBL2  ATP5C1  SNRPC  POMC  MYB  IRF4  IL12A  GFRA1  SEPP1   HCK  RRAS  GRN  PEPD  IFI30  DUSP6  LSP1  TAPBP  CD74  CTSS  SAMD1  CASP1  ANXA1  GAPDH  ANXA2  ATP6V1A  FGL2  LMO4  CYBA   BLK  CD79B  CD40  IRF8  MS4A1  NFKB1  CD22  IL10RA  CD83  TRAF5  S1PR1  ANK3  FCER2  LTB  HLA-DOA1  HLA-DOA  BCL2  HLA-DMA  CIITA  HLA-DMB  ATP1A1  SIPA1  C10BP  MIF  LEF1  U2AF1  CCND3  TUBB  IL7R  DDX51  RHOH   CD 28  SAE1  HLA-I  CD40 were ranged according to a hierarchical classification and annotated according to eight main categories (see legend): the immune (red), the nervous (green), the muscle (orange), the internal (dark blue), the secretory (purple), the reproductive (turquoise blue), the mucosa (yellow), and the cancer (black) types of samples. Some particular tissues from these categories are noted on the top: heart (H) and skeletal muscle (M) for the muscle type; testis (Te), prostate (P), and endometrium/myometrium (E/M) for the reproductive type; bone marrow (BM), thymus (Th), spleen (Sp), lymph node (LN) for the immune type; adipose (A), lung (Lu), trachea (Tr), intestine (I), stomach (St), kidney (K), and liver (Li) for the internal type. Four major gene clusters are indicated on the right by colored bars: black bar for overexpression in proliferating tissues; gray bar for ubiquitous overexpression across a large panel of tissue samples; red bar for specific overexpression in immune tissues; blue bar for preferential expression in the liver. (c) Expression profiles across a large compendium of blood cell types. The 681 cell samples (in columns) are ranged according to their respective positions in hematopoiesis (see tree on top) and pertain to eight main categories (see legend): the hematopoietic progenitors (gray) comprising the hematopoietic stem cells (HSC1-2) and the common myeloid (CMP) and myeloid/erythroid (MEP) progenitors; the erythroid lineage (orange) gathering early (eE) to late (lE) erythroid cells; the megakaryocytic category (pink) comprising megakaryocytes (M); the granulocyte/monocyte lineage (purple) comprising granulocyte/monocyte progenitors (GMP), granulocytes (G), monocytes (M), eosinophils (E), and basophils (B); the dentritic category (light blue) comprising dentritic cells (D1-2) ; the B-cell lineage (light green) gathering pre-B (PB) to mature B cells (B); the natural-killer (NK) lineage (dark green) comprising natural killers (NK); and the T-cell lineage (dark blue) gathering T CD8 (CD8) and T CD4 (CD4) lymphocyte populations. Expression from whole blood (WB), peripheral blood monocytes (PBMC), and peripheral lymphocytes (PL) is also shown on the left side. Four major gene clusters are indicated by colored bars on the right: orange bar for overexpression in proliferating progenitors; purple bar for overexpression in granulocyte/monocyte lineage; blue bar for higher expression in T-cell lineage; green bar for higher expression in B-cell lineage. (d) Tolerance expression profiles specificity of immune cell subtypes. The heat-map view on top details the genes predominantly overexpressed across cell types from the granulocyte/monocyte lineage (purple bar) including: granulocyte/monocyte (GM) progenitors, colony-forming unit (CFU) granulocytes, granulocytes, neutrophils, CFU and CD14 monocytes, eosinophils, and basophils. The heat-map view in middle shows the genes overexpressed in the CD8 and CD4 populations from the T lymphocyte lineage (blue bar) including the following cell subsets: naive, effector memory (TEM and TEMRA), and central memory (CM). The heat-map view on bottom depicts the genes having higher expression in cell subsets from the B-cell lineage (green bar) corresponding to: pre-B (including early and proB), naive B, mature B (gathering samples from B able to switch to fully switched B), and memory B (gathering immunoglobulin IgG and IgA and IgM-secreting B). For more details on the specificity of these gene expression profiles, results from pairwise comparisons (CD14 monocytes vs. B lymphocytes, CD14 monocytes vs. T lymphocytes, and T lymphocytes vs. B lymphocytes) along with expression in specific related cell lines (THP-1, Jurkat, and Raji) are also depicted on the top right of each heat-map view.
Their quantitative measurement by real-time PCR (independent technique) on a new collection of 67 samples (Figure 6b , Supplementary Figure SI15 online) yielded strong discrimination of TOL and STA (P ¼ 4.39E À 9): 16 markers (80%) were indeed altered (Po0.05) in the same sense. Leave-oneout prediction yielded excellent reproducibility (100% recall) on the 12 new time samples from already analyzed TOL cases and good external validation on the six new TOL cases (83.3% recall). Good classification (91.7%) was achieved (94.4% sensitivity, 90% specificity, 85% positive predictive value, and 96.4% negative predictive value), with one TOL and three STA being misclassified (Supplementary Figure  SI16 online) .
Altogether, these data show that the signature can be revalidated regardless of the study, the technology, and the sample provided. Figures  SI14 and SI15 online) . Altogether, these data show that TOL and HV display roughly the same 'healthy' profile.
DISCUSSION
Five studies were attempted to analyze tolerance through noninvasive blood transcriptomic analyses. [10] [11] [12] [13] [14] However, no significant overlap in the expression pattern could emerge. 12 In a first attempt to derive a consensus gene signature, we performed comparisons of gene lists generated from the five studies. Although valuable, 28 this approach unfortunately led to a limited 14-gene consensus, which is not sufficient to accurately detect tolerant among recipients. This result matches with our previous observations 12 as, by comparison, no overlap emerged from the five studies using a per-gene selection (Student's t-test, 5% false discovery rate). Such discrepancies, classically observed, [29] [30] [31] [32] [33] raise questions about the reproducibility, validity, and biological significance of microarray outcomes 34 when tested on independent data sets. 35 Inconsistencies are related to several factors. The different microarray platforms contain probes pertaining to different gene collections, ranging from dedicated 10, 11, 14 to all-genome. 12, 13 Such a disparity makes comparisons difficult 36 and it could reflect the poor percentage of crossvalidated genes (o1%). For that reason, the intersection of these platform gene lists is the only genes to be retained for further analysis. Microarray outcomes are also often limited by the small number of samples while analyzing thousands of genes, 37, 38 leading to underestimation of variances and reduction of statistic power. 39 This can be exacerbated in our situation knowing that blood samples can deeply vary between individuals [40] [41] [42] or even the day the sample was taken. 42, 43 In addition, the heterogeneity of the clinical outcome of these patients on the long term may add to these problems. 7 Moreover, gene lists are also greatly influenced by the subsets of the patients used for their selection, even in the same study, 35 and this could reflect the differences between the two cohorts (IOT and ITN) in the study by Sagoo et al.. 14 In light of this, it has been suggested that more samples are required to reach a decent level of marker stability. 44 This was the objective of our second attempt, consisting of the integration of all the initial data sets. Most of the metaanalysis approaches first identify a set of common genes across studies from which they then derive a gene expression signature. 36 Because of different data formats and experimental effects, 45, 46 direct comparison of raw data is difficult, not straightforward, and sometimes impossible even using standard normalization techniques. 47, 48 Standardization of the data obtained from individual research into values derived from a common scale before combination has been successfully applied. 49 We adopted this solution to identify a robust signature from the set of 1846 genes.
Our gene signature was defined owing to the metaanalysis of blood transcriptome studies comparing TOL with the more related group of STA patients. This group of patients was chosen as the most appropriate cohort to look at tolerance markers to identify the patients who may benefit from an IS-weaning protocol in the future. Of course, blood may not be the best compartment. However, disease gene profiles showed good concordance between blood and solid tissues. 50 In transplantation, gene changes in blood correlate with biopsy-proven rejection. [51] [52] [53] Moreover, rare cases of biopsies from tolerant cases did not evidence graft infiltrate, 8 suggesting that biopsy may not be informative. Conversely, blood is a promising source of therapeutic molecules, 54 and as it flows throughout the body it acts as a pipeline for the immune system and may be a good compartment to analyze complex patterns of recirculation. In tolerance, gene changes observed in blood may thus reflect active processes involving peripheral regulation 55 as attested by the characterization of regulatory molecules 56 and the possibility to induce tolerance with peripheral lymphocytes in animal models. 57 In this context, several cell types (B, CD4 T, and monocytes) may participate in the regulatory mechanisms as attested by related markers. Among all, the confirmation and identification of new B-cell markers appeared thus as one of the interesting findings reinforcing a suspected role for B lymphocytes in tolerance. 58 Indeed, B cells are able to drive immune responses 59 and there is compelling evidence that they act as multifaceted regulatory cells. [60] [61] [62] [63] [64] They may have a crucial role in regulating other cell subtypes reflecting the observed gene changes linked to CD4 T cells and CD14 monocytes. Moreover, although deep depletion of the B-cell compartment is associated with higher incidence rejection, 65 its preservation would be a prerequisite to favor the development of tolerance. 66 Interestingly, we found that most of the genes differentially expressed in TOL and STA were unchanged between TOL and HV both through the top-20 genes and the whole meta-analysis. Similar results were observed in previous studies both at transcriptional and cell phenotype levels. 13, 66 This suggests that, as previously mentioned, 67 tolerant patients may harbor a global preservation of their 'phenotype' , especially the B-cell compartment. It may contribute to maintain a physiological cell homeostasis counteracting inflammation and preserving a 'healthy profile' in these patients. To ascertain that our results are not the only reflection of the absence of treatment, we also look at these markers in patients with chronic rejection and off IS available in the study by Brouard et al. 11 As these patients harbor a highly differential profile from TOL, we reasonably exclude an effect of the absence of treatment (Supplementary Figure SI14 online ). Even more, these markers, particularly the B-cell ones, were not present in drug-free, operationally tolerant liver recipients. 12 Accordingly, operational tolerance in kidney transplants is more often detected in patients who have carried the graft, and thus IS, for a long time. 7, 8 In this case, long IS may create a immune restart 68, 69 towards a homeostatic equilibrium, as the one observed in healthy volunteers. 67 Finally, to assess the reliability of our signature, we first performed a full cross-validation procedure. This analysis yielded good predictions and enabled the validation of B cell-related markers (for example, BLK, BLNK, CD22, CD40, CD79B, CD83, FCER2, FCRL2, and MS4A1) but also genes related to other cell subsets including CD4 T (for example, CD150, CD28, CD52, and NFATC1) and CD14 monocyte (for example, CCR2, CD163, ITGAM, and ITGB2) molecules. For diagnosis purpose, a selection of the top-20 markers from this list, mostly centered on B cells, accurately discriminate tolerant from stable recipients. In a second step, these 20 markers were experimentally revalidated in an independent cohort of new TOL samples, from which six corresponded to new cases. These results showed that our initial findings were not dependent on the technology used or the analyzed set of samples. Both analyses yielded good prediction performances (more than 90%). Hence, our biomarkers could be reliably used to detect tolerance and stratify kidney recipients in clinics. First, they may help for a better follow-up of the tolerant patients. Indeed, several lines of evidence suggest that tolerance is likely not a stable situation for 'entire life' for most of the studied cases. 7 In such situations, immunotherapy could be reinstated before degradation of the graft. Second, these biomarkers may help to monitor kidney-transplanted recipients under classical IS. Such stable cases, presenting a low risk of rejection, would thus be highly eligible for progressive IS weaning. In our meta-analysis, 3% (eight cases) of the STA patients did express this signature and further examination of their clinical status revealed that they were still stable without degradation of renal function, years after the test. This result agreed previous observations ranking from 3.5 to 15%. 11, 14, 70, 71 However, only prospective studies of IS weaning in a controlled and randomized setting will enable proof of concept of this hypothesis.
In conclusion, our results indicated the participation of different immune cell subsets in natural operational tolerance. Among them, B cells certainly have a role in the maintenance of tolerance, reinforcing our previous observations. Although the implied regulations are still largely unknown, preservation of this compartment and maintenance of a physiological homeostasis and 'healthy profile' seem to be necessary for tolerance and may drive current therapies. According to its independent validation and its worldwide origin as collaboration between different teams, we hope that our signature, especially the restricted set of 20 markers, will aid in the identification of 'low-risk' patients among cohorts of transplanted recipients as recently performed for heart allograft rejection. 72 
MATERIALS AND METHODS

Data collection
The data used in this study were published [10] [11] [12] [13] [14] and are publicly available. The five microarray data sets and related information on samples were retrieved from Gene Expression Omnibus. They are referred to by the first author of the original publication and include studies from Braud (GSE47755), 10 Brouard (GSE47683), 11 Lozano (GSE22707), 12 Newell (GSE22229), 13 and Sagoo (GSE14655) 14 (Table 1) Figure SI18 online), and as most of these samples were collected at different time-points and processed on different platforms, they were thus analyzed as unique samples. The clinical definition of the patient groups has been described previously. [10] [11] [12] [13] [14] Meta-analysis To identify a gene signature of tolerance, the comparison was focused on the TOL group (n ¼ 96) and patients with stable graft function (n ¼ 343) either under standard (STA, n ¼ 311) or minimal immunotherapy (MIS, n ¼ 32). To this end, we performed two types of meta-analyses. The first captures in each individual data set the clusters of differential genes between the two groups and identifies the overlap as a consensus gene set. 12 The second relies on the integration of the different data sets as a single corpus of data 73 and identifies, after an analysis similar to the one performed on the individual data sets, the clusters of differentially expressed genes. Reprocessing, integration, and analysis Data sets were renormalized using a Lowess procedure, log-transformed, and median-centered on genes as previously described. [74] [75] [76] [77] [78] Probe annotation was performed using MADGene 79 to convert and match the genes across array platforms. Data sets were standardized 73 according to the STA group, before their integration and merging on the 1846 consensus genes. The relationship between genes and samples was investigated by hierarchical clustering using the Cluster program. 80 
Individualization of gene clusters and analysis
Ten clusters per data set (Supplementary Figure SI21 online) were individualized by K-means 81 and further analyzed by hierarchical clustering. 80 They were functionally interpreted by gene ontology, 82 gene set, 28 and virtual microdissection 83 analyses (Supplementary Figure SI22 online) . Their ability to statistically discriminate TOL and STA was evaluated by the Student's t-84 and Fisher's exact 85 tests. The discriminative clusters thus defined the 'signature' as previously shown. 20 
Independent reproducibility of the results
To confirm the functional and cellular components of the signature, we mined a large collection of 4658 public data sets from Gene Expression Omnibus (Supplementary Figure SI23 online) . Two blind analyses were performed, supported by the conservation of co-expressed genes across studies 86 and rank-based differences between two biological situations. 87 Cross-validation and classification performances The method was based on the following three parts: a gene selection based on T statistics, 88 a sample classifier based on support vector machine, 13 the best accurate one in our conditions (Supplementary Figure SI24 online), and a performance evaluation through cross-validation analysis. 89 The quality of the gene selection was determined by the classification performances (Supplementary Figure SI25 online) of the predictor over the six data sets. The discriminating capacity of the data was then evaluated by a leave-one-out strategy.
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